Comparison of the long-term efficacy of silodosin and tamsulodin for the tratment of benign prostatic hyperplasia

Comparison of the long-term efficacy of silodosin and tamsulodin for the tratment of benign prostatic hyperplasia - Long-term effect of silodosin and tamsulodin

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008538

Enrollment

200

Registered

2012-08-01

Start date

2006-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign prostatic hyperplasia

Interventions

Tamsulodsin Silodosin

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) a total IPSS of 8 or more, 2) maximum flow rate of 15 ml per second or less as evaluated by uroflowmetry, 3) prostate volume of 15 ml or more as measured by prostatic ultrasonography.

Exclusion criteria

Exclusion criteria: 1) with prostatic cancer, prostatitis and urethral stricture, 2) with severe cardiac or cerebrovascular disorders, hepatic disorders, renal dysfunction, 4) on medication with anti-cholinergics, other alpha-AR antagonists, Beta-AR agonists or antagonists, or anti-androgen drugs during 1 month prior to the study.

Design outcomes

Primary

Measure	Time frame
Changes in IPSS	—

Secondary

Measure	Time frame
Uroflowmetry, bladder diary	—

Countries

Japan

Contacts

Public ContactTomonori Yamanishi

Dokkyo Medical University Continence center

yamanish@dokkyomed.ac.jp0282-86-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026